

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
17 February 2022 (17.02.2022)



(10) International Publication Number  
**WO 2022/034044 A1**

- (51) **International Patent Classification:**  
*C07K 16/10* (2006.01) *A61P 31/14* (2006.01)
- (21) **International Application Number:**  
PCT/EP2021/072203
- (22) **International Filing Date:**  
09 August 2021 (09.08.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
63/063,862 10 August 2020 (10.08.2020) US  
63/112,104 10 November 2020 (10.11.2020) US
- (71) **Applicant: ASTRAZENECA UK LIMITED** [GB/GB];  
1 Francis Crick Avenue, Cambridge Biomedical Campus,  
Cambridge CB2 0AA (GB).
- (72) **Inventors: GASSER, Robert;** c/o MedImmune, LLC, One  
MedImmune Way, Gaithersburg, Maryland 20878 (US).  
**ESSER, Mark;** c/o MedImmune, LLC, One MedImmune  
Way, Gaithersburg, Maryland 20878 (US). **MCTAMNEY**  
**II, Patrick;** c/o MedImmune, LLC, One MedImmune Way,  
Gaithersburg, Maryland 20878 (US). **LOO, Yueh-Ming;** c/


o MedImmune, LLC, One MedImmune Way, Gaithersburg,  
Maryland 20878 (US). **VARKEY, Reena M.;** c/o MedIm-  
mune, LLC, One MedImmune Way, Gaithersburg, Mary-  
land 20878 (US). **DU, Qun;** c/o MedImmune, LLC, One  
MedImmune Way, Gaithersburg, Maryland 20878 (US).  
**STEINHARDT, James;** c/o AstraZeneca Pharmaceuticals  
LP, One MedImmune Way, Gaithersburg, Maryland 20878  
(US). **RAJAN, Saravanan;** c/o AstraZeneca Pharmaceu-  
ticals LP, One MedImmune Way, Gaithersburg, Maryland  
20878 (US).

(74) **Agent: MACLEAN, Martin Robert;** Mathys & Squire,  
The Shard, 32 London Bridge Street, London SE1 9SG  
(GB).

(81) **Designated States** (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) **Title:** SARS-COV-2 ANTIBODIES FOR TREATMENT AND PREVENTION OF COVID-19

FIGURE 2



(57) **Abstract:** The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of using such antibodies and antigen-binding fragments thereof for the prevention and treatment of Coronavirus Disease 2019 (COVID-19) in a subject.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

**(84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*